Exosomes are extracellular vesicles (EVs) of endosomal origin that range in size between 30 and 150 nanometers. Exosomes are secreted by a wide range of cells, since virtually all living cells utilize exosome-mediated communication. Exosomes carry cell-specific cargos of proteins, lipids, and nucleic acids that are selectively taken up by recipient cells. [Read more…]
Hopstem’s iPSC-Derived hNPC01 Cell Therapy Gains FDA Clearance to Target Three Major Brain Injury Indications
Hopstem Receives U.S. FDA IND Clearance and Fast Track designations for hNPC01 in Hemorrhagic Stroke and Traumatic Brain Injury-Expanding Clinical Development Across Three Major Brain Injury Indications
HOUSTON, July 29, 2026 — Hopstem Biotechnology announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application and Fast Track designations for hNPC01, an allogeneic induced pluripotent stem cell (iPSC)-derived forebrain neural progenitor cell therapy, for the treatment of chronic motor dysfunction due to Hemorrhagic Stroke (ICH) and Traumatic Brain Injury (TBI). [Read more…]
What is the difference between totipotent, pluripotent, and multipotent?
When learning about stem cells, a common question is, what is the difference between totipotent, pluripotent, and multipotent cells? The answer is simple.
The key differences between these cells are:
- When each appears during the process of human development.
- Their degree of “flexibility” to become other cell types. [Read more…]
What is Lab-Grown Meat and Why Does It Matter?
The potential of lab-grown meat has captured the attention of investors, researchers, food companies, and biotechnology leaders worldwide. Although the concept of producing meat from animal cells has existed for decades, the cultivated meat industry has evolved from an academic research field into an emerging commercial biotechnology sector. [Read more…]
China’s First Approved MSC Therapy, Ruibosheng, Hits the Market at a Fraction of Global Pricing
For years, the promise of mesenchymal stem cell (MSC) therapy has faced a stubborn barrier: cost. Even as regulators in South Korea, Japan, and other countries have cleared MSC-based products for commercial use, pricing for advanced cell therapies has often reached six figures, limiting access to a relatively small segment of patients and healthcare systems.
China’s first approved MSC therapy is challenging that assumption. Ruibosheng (amimestrocel injection), developed by Platinum Life Excellence Biotech, has entered the Chinese market at a price point that is a fraction of comparable cell therapies globally, highlighting how manufacturing innovation and scale may reshape the economics of regenerative medicine.
The National Medical Products Administration (NMPA) granted conditional approval to Ruibosheng on January 2, 2025, making it the first MSC-based cell therapy approved for market in China. The therapy was cleared for the treatment of steroid-refractory acute graft-versus-host disease (aGVHD) with predominant gastrointestinal involvement in patients aged 14 and older. Since receiving regulatory approval, Ruibosheng has progressed into commercial distribution and clinical adoption across Chinese hospitals. [Read more…]
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 339
- Next Page »